Shigeki Miyake Stoner
About Shigeki Miyake Stoner
Shigeki Miyake Stoner serves as the Director of R&D and Head of Technology at Replicate Bioscience, Inc., where he leads efforts in developing next-generation RNA vaccines and therapeutics. He has a strong background in genomic engineering and has previously held positions at notable institutions such as Viridos and the Salk Institute for Biological Studies.
Work at Replicate Bioscience
Shigeki Miyake Stoner serves as the Director of R&D and Head of Technology at Replicate Bioscience, Inc. since 2021. In this role, he leads research and development efforts aimed at advancing next-generation RNA vaccines and therapeutics. His focus is on bringing innovative solutions to clinical applications, contributing to the company's mission in the biotech sector.
Education and Expertise
Shigeki Miyake Stoner completed his Doctor of Philosophy (PhD) in Biology at the University of California San Diego from 2009 to 2017. He also holds Bachelor's Degrees in Chemistry, Biochemistry, and Molecular Biology from Franklin & Marshall College, which he attended from 2005 to 2009. His educational background provides a strong foundation for his expertise in genomic engineering and therapeutic development.
Background in Research and Development
Prior to his current position, Shigeki Miyake Stoner held various roles in research and development. He worked as a Scientist II in Algae Strain Engineering at Synthetic Genomics from 2017 to 2021. He also served as a Translational Scientist at the Salk Institute for Biological Studies from 2010 to 2017. His early career included a research position at Franklin & Marshall College, where he contributed as a Senior Research Associate from 2006 to 2009.
Achievements in Biotech Innovation
At Viridos, Shigeki Miyake Stoner developed self-replicating RNA replicon therapeutic vectors and vaccines, which led to the licensing of this technology to partners in human and animal health. He has also published several patents related to therapeutic viruses currently in clinical development at IconOVir. His work includes developing strategies for altering adenovirus tropism and manipulating virus genes for therapeutic purposes.
Consultation and Industry Contributions
Shigeki Miyake Stoner provides consultation in life biotech R&D, focusing on nucleic acid vectors, adenovirus, and other viral vectors for drug discovery and therapeutic development. His insights contribute to advancing the field of biotechnology and enhancing the development of innovative therapeutic solutions.